United States Food and Drug Administration (USFDA) has completed inspection at Lupin’s Tarapur manufacturing (API) facility. The inspection was carried out between September 16 to September 20, 2019. The inspection at the Tarapur facility closed with three observations.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.